secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioAtla, Inc. (BCAB)
CIK:        0001826892
Form:       8-K
Filed at:   2026-02-06T23:59:59+00:00
Accession:  0001193125-26-041367
Event type: regulatory
Sentiment:  negative
Materiality: 0.90
Item codes: 3.01, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

BioAtla receives Nasdaq delisting notice; trading suspension effective Feb 10
-----------------------------------------------------------------------------

- Nasdaq Hearings Panel determined to suspend BCAB common stock at open on Feb 10, 2026 for non-compliance with $1.00 bid price and $2.5M stockholders' equity requirements.
- Company requested immediate review and stay by Listing Council; Nasdaq counsel refused, but company claims precedent exists for such stays.
- If suspended, BCAB is expected to trade on OTC under same symbol, which may materially affect trading price and volume.
- As of Feb 6, $1.25M principal remained outstanding under Pre-Paid Advance Agreements; SEPA prohibits share sales during suspension.
- Company asserts Nasdaq improperly delayed compliance confirmation and secretly overturned long-standing reverse stock split policy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826892/000119312526041367/0001193125-26-041367-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826892/000119312526041367/bcab-20260206.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-041367

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer